The growth capacity of bone marrow CD34 positive cells in culture is drastically reduced in a murine model of Down syndrome

Beata Jablonska; David Ford; David Trisler; Bernard Pessac

doi:10.1016/j.crvi.2006.06.004

Medical sciences / Sciences médicales

The growth capacity of bone marrow CD34 positive cells in culture is drastically reduced in a murine model of Down syndrome
[Réduction drastique de la prolifération des cellules CD34⁺ cultivées à partir de la moelle osseuse de souris modèle du syndrome de Down]

Présenté par : Guy Blaudin de Thé

Beata Jablonska ¹ ; David Ford ^2,³ ; David Trisler ^2,³ ; Bernard Pessac ⁴

¹ Department of Pharmacology and Experimental Therapeutics, University of Maryland, School of Medicine, 655 W. Baltimore Street, Baltimore, MD 21201, USA
² Department of Neurology, University of Maryland, School of Medicine, 655 W. Baltimore Street, Baltimore, MD 21201, USA
³ Multiple Sclerosis Center of Excellence-East, Veterans Affairs Medical Center, Baltimore, MD 21201, USA
⁴ CNRS UMR 8118, unité de formation et de recherche biomédicale des Saints-Pères, 45, rue des Saints-Pères, 75006 Paris, France

Comptes Rendus. Biologies, Volume 329 (2006) no. 9, pp. 726-732.

Résumés

Anglais
Français

Human trisomy 21, Down syndrome (DS), is characterized by mental retardation. In addition, high risks of developing hematological and immune disorders, as well as cardiac, skeletal and other abnormalities are life-long concerns. Recent data suggested that bone marrow contains progenitors, hematopoietic or stromal cells, which may have the potential of generating non hematopoietic tissue such as neural cells, cardiac cells or osteoblasts. Therefore we have used a model of Down syndrome, Ts65Dn mice, to investigate their bone marrow. We have found that the vast majority of CD34⁺ cells in the bone marrow of adult Ts65Dn mice, but not of the CD34⁻ cells, exhibit a drastic reduction in their in vitro growth capacity. In addition to neural antigens, cultured CD34⁺ cells from trisomic and diploid mice also expressed mast cell markers.

La trisomie du chromosome 21 chez l'homme, ou syndrome de Down, est essentiellement caractérisée par un retard mental. Il existe en outre un risque élevé de désordres hématologiques et immunitaires ainsi que des anomalies diverses affectant entre autres le cœur, les os et les muscles tout au long de la vie. Des études récentes suggèrent que la moelle osseuse pourrait contenir des progéniteurs, cellules hématopoïétiques ou stromales qui pourraient éventuellement être à l'origine de tissus non hématopoïétiques tels que les cellules neurales, ostéoblastiques ou cardiaques. Nous avons donc étudié la moelle osseuse de la souris Ts65Dn, qui constitue un modèle de la trisomie 21. La très grande majorité des cellules CD34⁺, mais pas les cellules CD34⁻, sont apoptotiques, ce qui a pour résultat une diminution très importante de leur capacité de multiplication in vitro. En plus d'antigènes neuraux, les cellules CD34⁺ des souris trisomiques et diploïdes expriment également des marqueurs de mastocytes.

Métadonnées

Reçu le : 2005-09-29
Accepté le : 2006-06-15
Publié le : 2006-07-25

PMID

DOI : 10.1016/j.crvi.2006.06.004

Keywords: Down syndrome, Trisomic mice, Apoptosis, CD34⁺, Bone marrow
Mots-clés : Syndrome de Down, Souris trisomiques, Apoptose, CD34⁺, Moelle osseuse

Affiliations des auteurs :

Beata Jablonska ¹ ; David Ford ^{2, 3} ; David Trisler ^{2, 3} ; Bernard Pessac ⁴

¹ Department of Pharmacology and Experimental Therapeutics, University of Maryland, School of Medicine, 655 W. Baltimore Street, Baltimore, MD 21201, USA
² Department of Neurology, University of Maryland, School of Medicine, 655 W. Baltimore Street, Baltimore, MD 21201, USA
³ Multiple Sclerosis Center of Excellence-East, Veterans Affairs Medical Center, Baltimore, MD 21201, USA
⁴ CNRS UMR 8118, unité de formation et de recherche biomédicale des Saints-Pères, 45, rue des Saints-Pères, 75006 Paris, France

@article{CRBIOL_2006__329_9_726_0,
     author = {Beata Jablonska and David Ford and David Trisler and Bernard Pessac},
     title = {The growth capacity of bone marrow {CD34} positive cells in culture is drastically reduced in a murine model of {Down} syndrome},
     journal = {Comptes Rendus. Biologies},
     pages = {726--732},
     publisher = {Elsevier},
     volume = {329},
     number = {9},
     year = {2006},
     doi = {10.1016/j.crvi.2006.06.004},
     language = {en},
}

TY  - JOUR
AU  - Beata Jablonska
AU  - David Ford
AU  - David Trisler
AU  - Bernard Pessac
TI  - The growth capacity of bone marrow CD34 positive cells in culture is drastically reduced in a murine model of Down syndrome
JO  - Comptes Rendus. Biologies
PY  - 2006
SP  - 726
EP  - 732
VL  - 329
IS  - 9
PB  - Elsevier
DO  - 10.1016/j.crvi.2006.06.004
LA  - en
ID  - CRBIOL_2006__329_9_726_0
ER  -

%0 Journal Article
%A Beata Jablonska
%A David Ford
%A David Trisler
%A Bernard Pessac
%T The growth capacity of bone marrow CD34 positive cells in culture is drastically reduced in a murine model of Down syndrome
%J Comptes Rendus. Biologies
%D 2006
%P 726-732
%V 329
%N 9
%I Elsevier
%R 10.1016/j.crvi.2006.06.004
%G en
%F CRBIOL_2006__329_9_726_0

Beata Jablonska; David Ford; David Trisler; Bernard Pessac. The growth capacity of bone marrow CD34 positive cells in culture is drastically reduced in a murine model of Down syndrome. Comptes Rendus. Biologies, Volume 329 (2006) no. 9, pp. 726-732. doi : 10.1016/j.crvi.2006.06.004. https://comptes-rendus.academie-sciences.fr/biologies/articles/10.1016/j.crvi.2006.06.004/

Version originale du texte intégral

Le texte intégral ci-dessous peut contenir quelques erreurs de conversion par rapport à la version officielle de l'article publié.

1 Introduction

Human trisomy 21, Down syndrome (DS), is essentially characterized by mental retardation. In addition, the risk of developing hematological and immunological disorders is drastically increased in these patients [1,2]. A mouse model of human trisomy 21, Ts65Dn, has been produced with partial trisomy of chromosome 16, since its distal third is syntenic to the distal end of chromosome 21 and comprises 104 trisomic genes. Ts65Dn mice survive to adulthood and exhibit phenotypic abnormalities that resemble those of DS individuals [3].

We have recently reported that bone marrow cells from adult mice cultured with IL3, IL6 and SCF can be grown in culture over 30 generations, so that over a 4 month period of culture $1 \times 10^{15}$ cells were generated from $1 \times 10^{9}$ cells. These cells were CD34⁺, expressed the hematopoietic stem cell markers: Sca1, AA4.1, and cKit, as well as neural antigens [4].

It has been recently reported that the bone marrow contains progenitors – either hematopoietic or stromal cells – that have the potential of generating a variety of non-hematopoietic tissues such as neural cells, cardiac cells or osteoblasts [5–7]. These data suggested that it might be of interest to explore the properties of bone marrow cells of Ts65Dn mice. Therefore, these cells were put into culture in conditions identical to those previously used for normal mice.

The main result is that the in vitro growth capacity of bone marrow CD34⁺ cells from Ts65Dn mice is drastically reduced, yet they express a phenotype comparable to that of diploid cells.

2 Materials and methods

2.1 Mouse strains

The DS model mice – Ts(17¹⁶)65Dn (The Jackson Laboratory, Bar Harbor, ME) – were used in in vitro and ex vivo experiments. Diploid mice were the littermates of the Ts(17¹⁶)65Dn mice. These studies were conducted with the National Institutes of Health guidelines and the Institutional Animal Care Committee at University of Maryland (Baltimore, MD).

2.2 Preparation and experimental conditions of bone marrow cells

2.2.1 Preparation of ex vivo bone marrow cells

Bone marrow cells were obtained and prepared in the same way as reported previously [4]. Briefly, cells were collected aseptically from the femurs of Ts65Dn and diploid adult mice, fixed immediately in 4% paraformaldehyde, washed 2 times in 0.01M PBS (pH7.4) and deposited onto microscope slides by cytospin and stored at $- 80 ° C$ until use.

2.2.2 Preparation of in vitro bone marrow cells

The sample of cells from one adult mouse femur was suspended in 10 ml of DMEM (GIBCO Invitrogen, Carlsbad, CA) containing 10% FBS with the following supplements: 5 ng ml⁻¹ interleukin-3 (IL3), mouse 10 ng ml⁻¹ interleukin-6 (IL6), 10 ng ml⁻¹ mouse stem-cell factor (SCF) (R&D Systems, Minneapolis, MN), and a 1:1000 dilution of 10 μl 2-mercaptoethanol in 2.9 ml of H₂O. No matrix, substrate, or feeder cells were added to the liquid medium in the tissue-culture flasks. The medium was distributed into two T75 tissue-culture flasks to grow the cells at 37 °C in humidified 10% CO₂ in air. Passaging and feeding the cells with addition of 5 ml of fresh medium to each flask were usually done two times a week. Only the floating cells were passaged, leaving behind all the attached cells such as bone marrow stromal cells, endothelial cells, and macrophages, etc. Floating cells were subcultured in 50% conditioned medium from the previous culture and 50% fresh medium at $2 \times 10^{6}$ cells per 10 ml. After 3–4 weeks, the cultures contained only dividing floating cells, and the cells no longer differentiated into macrophages and other cells that attached to the flask. After 10 weeks of culture cells were fixed in 4% paraformaldehyde, washed two times in 0.01M PBS (pH7.4) and deposited onto microscope slides by cytospin and stored at $- 80 ° C$ until use.

2.3 Immunocytochemistry

Immunocytochemical studies were performed on ex vivo and in vitro bone marrow cells. Paraformaldehyde-fixed cells on microscope slides were treated with 0.25% Tween 20 for 3 min at 21°C, washed three times in PBS, and analyzed by standard immunocytochemistry methodology with the following antibodies: primary antibodies against CD34, Sca-1 (BD Pharmingen, San Diego, CA, USA), cKit (Cymbus Biotechnology, Chandlers Ford, UK), CD38 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), Ki67 (Novocastra Laboratories Ltd, Newcastle upon Tyne, UK). Additionally, for cultured cells staining the following antibodies were used: AA4.1, CD45 (BD Pharmingen), B220 (Santa Cruz Biotechnology), F4/80 (Serotec, Raleigh, NC, USA). After 1-h incubation in blocking buffer (0.01 M PBS, pH7.4, 10% Normal Goat Serum, 0.3% TritonX-100) with primary antibody the cells were washed three times in 0.01 M PBS buffer and then treated with the secondary antibody for one hour at room temperature. The following secondary antibodies were used: Alexa Fluor 546 F(ab′)₂ goat anti rabbit IgG H + L (Molecular Probes Invitrogen, Carlsbad, CA), Fluorescein (FITC) AffiniPure Goat Anti-Rat IgG (H + L), Fluorescein (FITC)-labeled F(ab′)₂ goat anti-rabbit, Rhodamine conjugated affinity Pure F(ab′)₂ goat anti-rat IgG (H + L) (Jackson ImmunoResearch Laboratories, West Grove, PA). After three washes in 0.01 M PBS (pH7.4) the cells were mounted in Vectashield mounting medium with DAPI (Vector Laboratories, Burlington, CA). In each labeling, we used the secondary antibody alone as a control.

2.3.1 TUNEL assay

Fixed cells from diploid and Ts65Dn were processed with cleaved caspase 3 (c-caspase 3) antibody (Cell Signaling Technology, Danvers, MA) and TUNEL by using an apoptosis detection kit (Roche Bioscience) following the manufacturer protocol. Cleaved caspase 3 antibody was used according to the immunocytochemical method described above.

2.3.2 BrdU labeling

To label mitotic bone marrow cells, 10-week-old cultures were incubated with one pulse of BrdU (final concentration 10 μM). After 5 h of incubation the cells were collected and prepared for immunolabeling as described above. Before labeling with the primary antibody the antigen retrieval was performed on the cultured cells using Retrievigen A (pH 6.0) (550524, BD Pharmingen) for 45 min. Then, a standard immunocytochemical protocol was carried out using anti-BrdU (1:100, 347580, Becton Dickinson, San Diego, CA) as a primary antibody and goat anti-mouse biotinylated IgG (1:300, BA-9200, Vector Laboratories) as a secondary antibody. The labeling was detected with DAB chromogen (Vector Laboratories).

2.3.3 Labeling of mast cells

Mast cells from various ages were labeled in two different ways. For histochemical analysis, cells were spun down, fixed in methanol, stained with 0.1% toluidine blue and then washed in PBS. For living cells we used FITC-conjugated anti-FcɛRIα antibody (eBioscience, San Diego, CA, USA) diluted in 0.1 M PBS (pH7.4) with 1% BSA, in a final concentration 1:200. After 30 min of incubation, the cells were washed three times in PBS.

2.4 Western blot analysis

Proteins from cultured CD34⁺ cells were separated by 10, 12, and 4–20% gradient polyacrylamide gel electrophoresis, transferred to nitrocellulose membranes as reported [4], and analyzed using specific antibodies against: cKit (CBL1359, Cymbus Biotechnology, Chandlers Ford, England), IL3R, IL6R (SC 681 and SC 13947, respectively, Santa Cruz Biotechnology), c-caspase 3 and p53 (9661S and 2524, respectively, Cell Signaling Technology).

3 Results

We have previously reported that bone marrow CD34⁺ cells from various diploid strains of mice are highly proliferative in culture and can grow as a pure population over 30 generations [4]. In the present study we have investigated the growth capacity in culture of bone marrow cells from TS65Dn mice in parallel with that of diploid littermates. Starting with the same number of bone marrow cells in diploid and Ts65Dn ( $2 \times 10^{6} cells$ ), the cell density of cultures was maintained at comparable levels during the growth curve measurements. After 80 days in culture, when all cells in diploid and trisomic cultures were CD34⁺, the cumulative number of CD34⁺ cells from Ts65Dn bone marrow was about 10⁹, while at the same time point, the number of cells from diploid littermates reached 10¹⁵ (Fig. 1A). To investigate the drastic reduction in in vitro proliferation of CD34⁺ bone marrow cells from trisomic mice, they were labeled with BrdU, a marker of S phase of the cell cycle and with Ki67 antibody, a marker of proliferating cells (Fig. 1B). Fig. 1B1 and B2 shows that only $10 \pm 2$ and $20 \pm 5 %$ , respectively, of the trisomic CD34⁺ cells were mitotically active compared to $70 \pm 1$ and $80 \pm 2 %$ , respectively, of diploid cells (t-test, $p < 0.01$ ). In parallel, the proportion of trisomic CD34⁺ cells exhibiting an apoptotic phenotype was more than 60%, versus less than 10% in diploid CD34⁺ cells as illustrated by c-caspase 3 (Fig. 1C1). Fig. 1C2 shows a much stronger expression of p53 signal in trisomic animals. In addition, the phenotype of the slow growing population of trisomic CD34⁺ cells was similar to that of diploid littermates. Both expressed the hematopoietic stem cell markers cKit and Sca1, but not the lineage specific markers listed in Fig. 1D. They both expressed markers found in neural cells as reported previously [7]. However, during the course of these studies, it has been reported that CD34⁺ bone marrow cells cultured in conditions similar to those we used expressed markers compatible with a mast cell phenotype [8]. We therefore investigated whether CD34⁺ cells cultured from bone marrow of Ts65Dn mice and their diploid littermates express a mast cell phenotype. Indeed, they both contained highly positive toluidine blue granules and were immunolabeled by FcɛRIα antibody (Fig. 2).

Fig. 1
(A) Growth curves of bone marrow cells of adult diploid (▵) and Ts65Dn (●) mice. In diploid cell cultures, the number of proliferating cells is 6–7 logs greater than in Ts65Dn cell cultures. (B, C) Cultures of bone marrow cells from diploid and Ts65Dn mice. All cells are CD34 positive and are labelled with DAPI (blue). (B) Mitosis detected by anti-BrdU and anti-Ki67 antibodies. The proportion of proliferating cells in Ts65Dn mice is significantly reduced. Graphs represent the percentage of BrdU⁺ (B1) and Ki67⁺ (B2) of CD34⁺ cells cultured for 6, 8 and 10 weeks. The values represent mean ± SEM. (C) Apoptosis of CD34⁺ cells detected by nuclear DAPI staining and anti-c-caspase 3 and anti-p53 antibodies. The number of apoptotic cells is significantly higher in Ts65Dn cultures than in diploid. White arrows point to apoptotic nuclei. (C1) Graph represents the percentage of cells expressing c-caspase 3 in CD34⁺ cultures from diploid and Ts65Dn mice at 6, 8 and 10 weeks. In Ts65Dn cultures, the number of apoptotic cells is much higher than in diploid cultures. The data represent mean ± SEM, c-caspase 3 stands for cleaved caspase 3. (C2) Western blot analysis shows the presence of p53 in CD34⁺ cells of Ts65Dn cultured for six weeks. TA, TC – individual trisomic mice, DA, DE – individual diploid mice. (D) Phenotypic markers in 10-week-old cultures of CD34⁺ cells from diploid and Ts65Dn mice. Masquer
(A) Growth curves of bone marrow cells of adult diploid (▵) and Ts65Dn (●) mice. In diploid cell cultures, the number of proliferating cells is 6–7 logs greater than in Ts65Dn cell cultures. (B, C) Cultures of bone marrow cells ... Lire la suite

Fig. 2
14 and 25 day-old cultures of bone marrow cells stained with (A) toluidine blue and (B) anti-FcɛRIα antibody. The number of cells containing grey granules or expressing FcɛRIα receptors, specific for mast cells, greatly increases between 14 and 25 DIC. DIC: Days In Culture.

Taken together, these data indicate that the populations of the bone marrow CD34⁺ cells in culture from trisomic and diploid mice are comparable, except for their growth capacity, which is drastically reduced in cells from trisomic mice. Therefore we investigated which mechanisms could account for the low growth of CD34⁺ cells from Ts65Dn mice. One obvious possibility is that the cells lack receptors for the cytokines used in these experiments. However, as shown in Fig. 3, receptors for IL3 and IL6 were detected at comparable levels in CD34⁺ cultures from diploid and trisomic mice. We then asked the question whether CD34⁺ cells from ex vivo bone marrow of trisomic mice expressed markers which may account for the defective growth capacity of these cells. The percentage of ex vivo bone marrow CD34⁺ cells from diploid and Ts65Dn mice was comparable ( $8 \pm 0.6 %$ and $5 \pm 0.4 %$ respectively). The vast majority of CD34⁺ cells from trisomic mice $(76 \pm 6.2 %)$ exhibited an abnormal nuclear morphology as opposed to a minority $(21 \pm 1.9 %)$ in their diploid littermates (t-test, $p < 0.01$ , data not shown). Double labeling of ex vivo bone marrow cells with CD34⁺ and TUNEL or c-caspase 3 markers (Fig. 4A) indicated that the vast majority of CD34⁺ cells in Ts65Dn mice might enter the apoptosis pathway, while virtually no CD34⁻ expressed apoptotic markers. Moreover, the percentage of double labeled cells with p53 and CD34 was higher in the trisomic versus normal littermates. When ex vivo CD34⁺ cells from both of types of mice were stained with Ki67 (Fig. 4B) only $28 \pm 4.5 %$ of trisomic CD34⁺ cells were immunolabeled versus $89 \pm 5.0 %$ of diploid cells (t-test, $p < 0.01$ ). Then, we investigated the phenotype of ex vivo CD34⁺ cells from trisomic and control mice. Fig. 4B shows that they both expressed c-Kit, sca-1 and CD38 markers present in hematopoietic stem cells. Thus, CD34⁺ cells from trisomic mice, although the majority of them appear apoptotic, seem to be a population similar to that of their diploid littermates. In sharp contrast, in the CD34⁻ cell population, which represents 90–95% of all nucleated bone marrow cells in mice, only 1–3% exhibited an abnormal nuclear morphology and was labeled with TUNEL, c-caspase 3 or p53 markers. It is of interest that the blood cell counts of Ts65Dn mice are not significantly different from those of diploids (data not shown).

Fig. 3
Western blot analysis of IL3 and IL6 receptors in Ts65Dn and diploid cultures. Equal amounts of total cell protein were added as shown by the level of c-kit expression DC: individual diploid mouse; TA TB, TC: individual trisomic mice.

Fig. 4
(A) All cells are stained with DAPI (blue), CD34 positive cells are red, and cells stained for TUNEL, c-caspase 3 or Ki67 are green, yellow cells are triple stained with DAPI, CD34 and TUNEL, or c-caspase 3, or Ki67 (white arrowheads). (B) The percentage of cells double labeled by CD34 and c-caspase3, or TUNEL, or p53 is significantly higher in Ts65Dn mice. Conversely, the percentage of cells double labeled with CD34 and Ki67 is much higher in diploid mice. In contrast, the hematopoietic markers: c-Kit, Sca1 and CD38 label the vast majority of CD34⁺ cells both in diploid and trisomic mice. Masquer
(A) All cells are stained with DAPI (blue), CD34 positive cells are red, and cells stained for TUNEL, c-caspase 3 or Ki67 are green, yellow cells are triple stained with DAPI, CD34 and TUNEL, or c-caspase 3, or Ki67 (white ... Lire la suite

4 Discussion

The main finding of this report is that a distinct population of bone marrow cells characterized by expression of the CD34⁺ molecule exhibits a marked decrease in in vitro growth capacity in mice which have a triplication of the chromosome homologous to human chromosome 21, as compared to diploid mice. In this chromosome, the region syntenic to the human chromosome 21 contains 104 triplicated genes. Which product(s) of the trisomic genes [9] are expressed the apoptosis of bone marrow CD34-positive cells and leads to their drastically decreased growth capacity? Among them, some are known to be involved in cell cycle and apoptosis, such as Sod-1, an antioxidant enzyme, whose overexpression leads to a hypoplastic thymus and bone marrow abnormalities [10] or the transcription factor Runx1 [11] which codes for AML-1, involved in hematopoiesis regulation and also in DS leukemias [12]. We have also shown that the apoptotic p53 protein is increased in trisomic CD34⁺ cells, possibly as a result of overexpression of the transcription factor ets-2, which binds to the promoters of p53 gene as well as to that of p21, a regulator of cell proliferation [13–15]. The most surprising result of this study is that the presence of apoptotic markers is strictly restricted to CD34⁺ cells. We may speculate that the CD34 protein or associated proteins contribute to a transduction process involved in an apoptosis pathway. It will be therefore of interest to compare expression of above genes, among others, in the homogeneous population of cells expressing CD34⁺ versus CD34⁻ cells and as well to measure the effect of trisomic gene expression on the pattern of non-trisomic gene expression in CD34⁺ cells. It has already been shown in Ts65Dn and in another model of Down syndrome-Ts16 mice, that there is increased apoptosis in the nervous system in the hippocampus [16] and cortical neurons [17], thymus [2,4,18] and germ cells [19]. Indeed, it has been reported that during the development of the neocortex of the Ts16 mouse, as compared to controls, a smaller proportion of progenitors that exit the cells cycle, a longer cell cycle, and a reduced growth fraction, as well as an increase in apoptosis [20]. The trisomy model of stem-cell proliferation may yield the genetic basis of a general mechanism for control of the balance of cell mitosis and apoptosis. Finally, it may be of interest that the slowly growing Ts65Dn CD34⁺ cells in the culture display a mast cell phenotype because of the role of these cells in inflammatory and immunoregulatory processes [21].

Acknowledgements

We thank Dr. A. Costa from Eleanor Roosevelt Institute of University of Denver for providing Ts65Dn and diploid mice. We also would like to thank S. Clark for help with analyzing in vitro data and T. Wright for maintaining cultures, Dr. P. Yarowsky for discussion, and Dr. D. Ogden for reading the manuscript. This work was supported by the Department of Veterans Affairs Merit Review (D.T.) and the ‘Fondation Jérôme-Lejeune’, France (B.P.).

Bibliographie

[1] A. Cossarizza; D. Monti; G. Montagnani; C. Ortolani; M. Masi; M. Zannotti; C. Franceschi Precocious aging of the immune system in Down syndrome: alteration of B lymphocytes, T-lymphocyte subsets, and cells with natural killer markers, Am. J. Med. Genet., Volume 7 (1990) no. Suppl., pp. 213-218

[2] H. Hasle Pattern of malignant disorders in individuals with Down's syndrome, Lancet Oncol., Volume 2 (2001), pp. 429-436

[3] R.H. Reeves; N.G. Irving; T.H. Moran; A. Wohn; C. Kitt; S.S. Sisodia; C. Schmidt; R.T. Bronson; M.T. Davisson A mouse model for Down syndrome exhibits learning and behaviour deficits, Nat. Genet., Volume 11 (1995), pp. 177-184

[4] J. Goolsby; M.C. Marty; D. Heletz; J. Chiappelli; G. Tashko; D. Yarnell; P.S. Fishman; S. Dhib-Jalbut; C.T. Bever; B. Pessac; D. Trisler Hematopoietic progenitors express neural genes, Proc. Natl Acad. Sci. USA, Volume 100 (2003), pp. 14926-14931

[5] M. Dominici; C. Pritchard; J.E. Garlits; T.J. Hofmann; D.A. Persons; E.M. Horwitz Hematopoietic cells and osteoblasts are derived from a common marrow progenitor after bone marrow transplantation, Proc. Natl Acad. Sci USA, Volume 101 (2004), pp. 11761-11766

[6] K. Dorshkind Multilineage development from adult bone marrow cells, Nat. Immunol., Volume 3 (2002), pp. 311-313

[7] O.E. Sigurjonsson; M.C. Perreault; T. Egeland; J.C. Glover Adult human hematopoietic stem cells produce neurons efficiently in the regenerating chicken embryo spinal cord, Proc. Natl Acad. Sci. USA, Volume 102 (2005), pp. 5227-5232

[8] E. Drew; H. Merkens; S. Chelliah; R. Doyonnas; K.M. McNagny CD34 is a specific marker of mature murine mast cells, Exp. Hematol., Volume 30 (2002), p. 1211

[9] K. Gardiner; A. Fortna; L. Bechtel; M.T. Davisson Mouse models of Down syndrome: how useful can they be? Comparison of the gene content of human chromosome 21 with orthologous mouse genomic regions, Gene, Volume 318 (2003), pp. 137-147

[10] M. Peled-Kamar; J. Lotem; E. Okon; L. Sachs; Y. Groner Thymic abnormalities and enhanced apoptosis of thymocytes and bone marrow cells in transgenic mice overexpressing Cu/Zn-superoxide dismutase: implications for Down syndrome, EMBO J., Volume 14 (1995), pp. 4985-4993

[11] M. Ichikawa; T. Asai; T. Saito; S. Seo; I. Yamazaki; T. Yamagata; K. Mitani; S. Chiba; S. Ogawa; M. Kurokawa; H. Hirai AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis, Nat. Med., Volume 10 (2004), pp. 299-304

[12] C. Gjertson; K. Sturm; C. Berger Hematopoietic deficiencies and core binding factor expression in murine Ts16, an animal model for down syndrome, Clin. Immunol., Volume 91 (1999), pp. 50-60

[13] T. Cheng; N. Rodrigues; H. Shen; Y. Yang; D. Dombkowski; M. Sykes; D.T. Scadden Hematopoietic stem cell quiescence maintained by p21cip1/waf1, Science, Volume 287 (2000), pp. 1804-1808

[14] J. Lotem; L. Sachs Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents, Blood, Volume 82 (1993), pp. 1092-1096

[15] V.I. Sementchenko; D.K. Watson Ets target genes: past, present and future, Oncogene, Volume 19 (2000), pp. 6533-6548

[16] L.L. Bambrick; B.K. Krueger Neuronal apoptosis in mouse trisomy 16: mediation by caspases, J. Neurochem., Volume 72 (1999) no. 4, pp. 1769-1772

[17] S. Schuchmann; W. Muller; U. Heinemann Altered Ca²⁺ signaling and mitochondrial deficiencies in hippocampal neurons of trisomy 16 mice: a model of Down's syndrome, J. Neurosci., Volume 18 (1998), pp. 7216-7231

[18] C.J. Epstein; B.G. Hofmeister; D. Yee et al. Stem cell deficiencies and thymic abnormalities in fetal mouse trisomy 16, J. Exp. Med., Volume 162 (1985) no. 2, pp. 695-712

[19] A. Leffler; M. Ludwig; O. Schmitt; L.C. Busch Germ cell migration and early development of the gonads in the trisomy 16 mouse – an animal model for Down's syndrome, Ann. Anat., Volume 181 (1999) no. 3, pp. 247-252

[20] T.F. Haydar; R.S. Nowakowski; P.J. Yarowsky; B.K. Krueger Role of founder cell deficit and delayed neuronogenesis in microencephaly of the trisomy 16 mouse, J. Neurosci., Volume 20 (2000) no. 11, pp. 4156-4164

[21] S.J. Galli; J. Kalesnikoff; M.A. Grimbaldeston; A.M. Piliponsky; C.M. Williams; M. Tsai Mast cells as ‘tunable’ effector and immunoregulatory cells: Recent advances, Annu. Rev. Immunol., Volume 23 (2005), pp. 749-786

Cité par

Nicola R. Mason; Hilary Cahill; Yonatan Diamond; Karen McCleary; Rishi S. Kotecha; Glenn M. Marshall; Marion K. Mateos Down syndrome-associated leukaemias: current evidence and challenges, Therapeutic Advances in Hematology, Volume 15 (2024) | DOI:10.1177/20406207241257901
Bridgette G. J. O’ Malley; Huong Duong; Georgia Kafer; Michelle Maugham-Macan The aetiology of atypical bone health in individuals with Down syndrome, Archives of Osteoporosis, Volume 18 (2023) no. 1 | DOI:10.1007/s11657-023-01348-1
Laszlo Pecze; Elisa B. Randi; Csaba Szabo Meta-analysis of metabolites involved in bioenergetic pathways reveals a pseudohypoxic state in Down syndrome, Molecular Medicine, Volume 26 (2020) no. 1 | DOI:10.1186/s10020-020-00225-8
Nathan Duval; Guido N. Vacano; David Patterson Rapamycin Treatment Ameliorates Age-Related Accumulation of Toxic Metabolic Intermediates in Brains of the Ts65Dn Mouse Model of Down Syndrome and Aging, Frontiers in Aging Neuroscience, Volume 10 (2018) | DOI:10.3389/fnagi.2018.00263
Catherine Do; Zhuo Xing; Y Eugene Yu; Benjamin Tycko Trans-Acting Epigenetic Effects of Chromosomal Aneuploidies: Lessons From Down Syndrome and Mouse Models, Epigenomics, Volume 9 (2017) no. 2, p. 189 | DOI:10.2217/epi-2016-0138
Noemí Rueda; Jesús Flórez; Carmen Martínez-Cué Apoptosis in Down’s syndrome: lessons from studies of human and mouse models, Apoptosis, Volume 18 (2013) no. 2, p. 121 | DOI:10.1007/s10495-012-0785-3
Iman Ehsan Abdel-Meguid; Ekram Abdel-Salam; Doaa M Abdel Latif; Soheir Korraa; Amal Ismaiel Markers of neural degeneration and regeneration in Down syndrome patients, Egyptian Journal of Medical Human Genetics, Volume 14 (2013) no. 1, p. 49 | DOI:10.1016/j.ejmhg.2012.08.008
Guido N. Vacano; Nathan Duval; David Patterson The Use of Mouse Models for Understanding the Biology of Down Syndrome and Aging, Current Gerontology and Geriatrics Research, Volume 2012 (2012), p. 1 | DOI:10.1155/2012/717315
Valerio Costa; Claudia Angelini; Luciana D'Apice; Margherita Mutarelli; Amelia Casamassimi; Linda Sommese; Maria Assunta Gallo; Marianna Aprile; Roberta Esposito; Luigi Leone; Aldo Donizetti; Stefania Crispi; Monica Rienzo; Berardo Sarubbi; Raffaele Calabrò; Marco Picardi; Paola Salvatore; Teresa Infante; Piergiuseppe De Berardinis; Claudio Napoli; Alfredo Ciccodicola; Diego Di Bernardo Massive-Scale RNA-Seq Analysis of Non Ribosomal Transcriptome in Human Trisomy 21, PLoS ONE, Volume 6 (2011) no. 4, p. e18493 | DOI:10.1371/journal.pone.0018493
Valerio Costa; Linda Sommese; Amelia Casamassimi; Roberta Colicchio; Claudia Angelini; Valentina Marchesano; Lara Milone; Bartolomeo Farzati; Alfonso Giovane; Carmela Fiorito; Monica Rienzo; Marco Picardi; Bice Avallone; Massimiliano Marco Corsi; Berardo Sarubbi; Raffaele Calabrò; Paola Salvatore; Alfredo Ciccodicola; Claudio Napoli Impairment of circulating endothelial progenitors in Down syndrome, BMC Medical Genomics, Volume 3 (2010) no. 1 | DOI:10.1186/1755-8794-3-40
Kristi Kerkel; Nicole Schupf; Kota Hatta; Deborah Pang; Martha Salas; Alexander Kratz; Mark Minden; Vundavalli Murty; Warren B. Zigman; Richard P. Mayeux; Edmund C. Jenkins; Ali Torkamani; Nicholas J. Schork; Wayne Silverman; B. Anne Croy; Benjamin Tycko; Dirk Schübeler Altered DNA Methylation in Leukocytes with Trisomy 21, PLoS Genetics, Volume 6 (2010) no. 11, p. e1001212 | DOI:10.1371/journal.pgen.1001212
Sébastien Malinge; Shai Izraeli; John D. Crispino Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome, Blood, Volume 113 (2009) no. 12, p. 2619 | DOI:10.1182/blood-2008-11-163501
Inés Colmegna; Alejandro Diaz‐Borjon; Hiroshi Fujii; Linda Schaefer; Jörg J. Goronzy; Cornelia M. Weyand Defective proliferative capacity and accelerated telomeric loss of hematopoietic progenitor cells in rheumatoid arthritis, Arthritis Rheumatism, Volume 58 (2008) no. 4, p. 990 | DOI:10.1002/art.23287
Gina Kirsammer; Sarah Jilani; Hui Liu; Elizabeth Davis; Sandeep Gurbuxani; Michelle M. Le Beau; John D. Crispino Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome, Blood, Volume 111 (2008) no. 2, p. 767 | DOI:10.1182/blood-2007-04-085670

Cité par 14 documents. Sources : Crossref

Commentaires - Politique